-
Multiple Sclerosis and Related Disorders May 2024
Topics: Humans; Multiple Sclerosis
PubMed: 38574723
DOI: 10.1016/j.msard.2024.105575 -
The Neurologist Mar 2010Pediatric multiple sclerosis (MS), once considered a rare childhood illness, has been increasingly identified as an important childhood acquired neurologic disease... (Review)
Review
BACKGROUND
Pediatric multiple sclerosis (MS), once considered a rare childhood illness, has been increasingly identified as an important childhood acquired neurologic disease requiring early recognition and intervention.
SUMMARY
We present a comprehensive review of the current terminology of acquired central nervous system demyelination in children, pertinent investigations, including magnetic resonance imaging and cerebrospinal fluid cerebrospinal fluid studies, and an approach to the differential diagnosis of pediatric onset MS. In addition, the recent studies exploring the epidemiology and pathobiology will be discussed. Finally, we present an algorithm for the treatment of episodes of demyelination along with chronic immunomodulatory therapeutic options in this patient population.
CONCLUSIONS
Although some similarities exist to adult onset MS, MS onset during childhood and adolescence presents unique diagnostic challenges and requires specialized multidisciplinary care for optimal management. National and international collaborative studies are underway to aid in the understanding of the early and ongoing pathogenesis of MS.
Topics: Child; Diagnosis, Differential; Humans; Multiple Sclerosis; Prognosis
PubMed: 20220443
DOI: 10.1097/NRL.0b013e3181c923d5 -
La Revue Du Praticien Jun 2013
Review
Topics: Adult; Diagnosis, Differential; Humans; Multiple Sclerosis; Palliative Care; Risk Factors; Young Adult
PubMed: 23923767
DOI: No ID Found -
La Revue Du Praticien Apr 2020
Topics: Disease Progression; Humans; Multiple Sclerosis
PubMed: 32877115
DOI: No ID Found -
Journal of Neurology Aug 2023Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system (CNS), which also affects the autonomic nervous system (ANS).... (Review)
Review
Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system (CNS), which also affects the autonomic nervous system (ANS). Manifestations of MS in the ANS include urological, sexual, gastrointestinal, cardiovascular, and thermoregulatory disorders as well as increased fatigue. These problems are common yet are often underestimated due to the non-specificity of the symptoms and the limited evaluation of the ANS in the usual clinical practice. Most of these symptoms seem to be related to localized lesions in the CNS. However, the mechanisms by which these disorders are caused in MS have not been fully investigated, thus preventing any focused etiological treatment. The most common disorders of the ANS in MS represent a challenge for clinicians due to the variability of the clinical picture and our minimal data on their diagnosis and treatment. Early diagnosis and initiation of individualized treatment regimens, often in need of multiple approaches, seem to yield the best results in managing ANS dysfunction in MS patients.
Topics: Humans; Multiple Sclerosis; Autonomic Nervous System Diseases; Autonomic Nervous System; Central Nervous System
PubMed: 37084150
DOI: 10.1007/s00415-023-11725-y -
Medicina Clinica Dec 2014
Topics: Humans; Multiple Sclerosis
PubMed: 25732941
DOI: 10.1016/S0025-7753(15)30001-4 -
Revue Neurologique Jun 2018
Topics: Humans; Multiple Sclerosis
PubMed: 29903397
DOI: 10.1016/j.neurol.2018.04.008 -
Nature Apr 2012
Topics: Humans; Multiple Sclerosis; Young Adult
PubMed: 22509502
DOI: 10.1038/nature11104 -
Radiologic Technology 2006Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that usually first affects people in their 20s or 30s. MS is one of the most... (Review)
Review
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that usually first affects people in their 20s or 30s. MS is one of the most common causes of nontraumatic disability among young and middle-aged individuals. Because symptoms of MS are extremely variable and often quite subtle, the use of magnetic resonance (MR) imaging plays a crucial role in diagnosis and management. Early diagnosis and treatment can slow the progression and limit the impact of this potentially devastating disease.
Topics: Contrast Media; Diagnostic Imaging; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Multiple Sclerosis
PubMed: 16543484
DOI: No ID Found -
Multiple Sclerosis (Houndmills,... Apr 2020Multiple sclerosis (MS) is associated with changes in the metabolome. Numerous studies employing varying metabolomics platforms have examined a range of biological... (Review)
Review
Multiple sclerosis (MS) is associated with changes in the metabolome. Numerous studies employing varying metabolomics platforms have examined a range of biological material ranging from brain tissue to urine and demonstrated consistently alterations in multiple metabolic pathways in MS. We review not only the studies that describe the ability of metabolomics to differentiate MS patients from healthy controls and other neurological disease but also discuss the potential of metabolomics-based methods to build predictive models that are able to stage disease, monitor progression, and select the most appropriate therapy. The increasing number of impressive claims for the capacity of metabolomics to distinguish between different types of demyelinating disease suggests that the provision of such tests may be close at hand. Besides the ability to provide potential diagnostic and prognostic biomarkers, metabolomics also provides us with unique insights into the pathophysiology of the disease and helps identify metabolic pathways that may be potential therapeutic targets. Future studies will integrate metabolomics data with other omics techniques to provide further insight into the source of these metabolic abnormalities and help with identification of the most promising targets for therapeutic intervention.
Topics: Disease Progression; Humans; Metabolome; Metabolomics; Multiple Sclerosis; Precision Medicine
PubMed: 31965880
DOI: 10.1177/1352458519876020